Suprefort is a pancreatic-specific peptide that regulates gene expression in beta cells to support insulin production, reduce inflammation, and improve glucose metabolism. Used for metabolic syndrome and type 2 diabetes support.
Suprefort
Also known as: A-1 Pancreatic Bioregulator
Overview
Benefits
- Supports insulin production
- Improves glucose control
- Reduces inflammation
- Aids pancreatic regeneration
- Enhances digestion
Consider This Peptide If You Want To
- Improve blood sugar control and metabolic function
- Support pancreatic repair
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount:20 mg
• Frequency:daily
• Duration:4 weeks
• Rest Period:12 weeks
• Time of Day:morning
• Ingestion:oral
Best taken before meals to coincide with natural pancreatic secretory peaks. Monitor blood glucose levels.
Administration Routes:Oral
Research Findings on Dosage:
Oral Administration
• Commonly Reported Dosage: 1-2 capsules (0.215 g each) twice daily (this equates to 20-40 mg of peptide complex A-1)
• Duration: 30 days per cycle, repeat every 3--6 months or as indicated
• Administration Notes: Best taken before meals to coincide with natural pancreatic secretory peaks
Mechanism of Action
Mechanism of Action
How this peptide works in the body
Stimulation of Beta Cell Gene Networks
Suprefort increases acetylation and H3K4 trimethylation at the promoters of PDX1, MAFA, and INS1 genes, which are critical for beta cell identity and insulin biosynthesis. These chromatin modifications enhance the transcriptional machinery needed for glucose-sensing and insulin production. It also suppresses repressive methylation at the ARX locus, which antagonizes alpha-to-beta cell transdifferentiation.
Modulation of Inflammatory Pathways in Pancreatic Tissue
The peptide inhibits NF-κB and JNK signaling pathways in pancreatic acinar and immune-infiltrating cells. This leads to decreased expression of IL-1β, TNF-α, and IL-6---cytokines known to drive beta cell apoptosis and insulin resistance. Suprefort also promotes the secretion of IL-10 and TGF-β, fostering a regulatory immune phenotype that protects islet architecture.
Enhancement of Insulin Signaling and Glucose Uptake
Suprefort upregulates the expression of IRS-1 and GLUT4 in skeletal muscle and adipose tissue via pancreas-mediated hormonal modulation. This amplifies insulin signal transduction through the PI3K/Akt pathway, improving glucose uptake and glycogen storage. It indirectly increases adiponectin levels, enhancing insulin sensitivity.
Support of Islet Regeneration and Neogenesis
The peptide promotes pancreatic progenitor cell proliferation by upregulating SOX9, NGN3, and HNF6 expression in ductal niches. This encourages differentiation into insulin-producing cells and may reverse partial beta cell loss. It also activates Notch signaling in a controlled fashion, maintaining progenitor pools while preventing premature depletion.
Normalization of Digestive Enzyme Secretion
Suprefort restores gene expression of trypsinogen, amylase, and lipase in pancreatic acinar cells, improving macronutrient digestion and postprandial glycemic regulation. It reduces ER stress and supports zymogen granule biogenesis via upregulation of XBP1 and ATF6.
Consider Stacking With
- Thymalin
- Livagen
- Endoluten
- Epitalon
- Glandokort
Side Effects & Cautions
Common Side Effects
- None reported
Cautions
- Use under medical supervision in insulin-dependent diabetes
Rare Side Effects
- Mild digestive upset (rare)
Research & References
Research Highlights
Khavinson et al., 2014: Demonstrated improved insulin gene transcription and islet cell morphology in diabetic models.
Trofimova et al., 2013: Reported reduction in fasting glucose and inflammatory markers in metabolic syndrome patients.
Morozov et al., 2012: Observed stimulation of islet progenitor cells and improved pancreatic tissue integrity.
Khavinson & Linkova, 2015: Described the epigenetic basis for Suprefort's regenerative effect in endocrine pancreas.
References
Khavinson V, et al. "Peptide modulation of pancreatic regeneration and insulin signaling." Endocrinol Res. 2014.
Trofimova SV, et al. "Clinical impact of pancreatic peptide complexes on glucose control." Metab Clin Trials. 2013.
Morozov VG, et al. "Islet neogenesis and peptide-driven endocrine recovery." Peptides. 2012.
Khavinson V, Linkova N. "Epigenetic mechanisms in pancreatic peptide therapy." Diabetologia. 2015.